Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mind Medicine Mindmed Inc (NQ: MNMD ) 6.610 +0.190 (+2.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mind Medicine Mindmed Inc < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years September 12, 2023 NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. Via Benzinga MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone September 12, 2023 MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders, Via Benzinga MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) September 12, 2023 From Mind Medicine (MindMed) Inc. Via Business Wire Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Analyst Expectations for Mind Medicine's Future August 22, 2023 Via Benzinga What 9 Analyst Ratings Have To Say About Mind Medicine August 04, 2023 Via Benzinga 6 Largest Psychedelic Compound-Based R & D Stocks In Decline September 10, 2023 The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. Via Talk Markets The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction September 07, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property 6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week September 05, 2023 The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. Via Talk Markets Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More September 05, 2023 Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Via Benzinga Mind Science Targeting Big Brains and Portfolios August 02, 2023 Via AB Newswire August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15% September 02, 2023 The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. Via Talk Markets Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More August 28, 2023 Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials Via Benzinga MindMed to Participate at September Investor Conferences August 28, 2023 From Mind Medicine (MindMed) Inc. Via Business Wire 6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week August 25, 2023 Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. Via Talk Markets Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports August 21, 2023 Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds Via Benzinga Topics Cannabis Economy Exposures Cannabis Interest Rates Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend August 20, 2023 The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... Via Talk Markets MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year August 14, 2023 Clinical-stage psychedelics biotech MindMed (NASDAQ: MNMD) has secured a new financing source by entering into a $50 million senior secured credit facility with K2 HealthVentures, an alternative... Via Benzinga Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More August 14, 2023 First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published Via Benzinga MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures August 14, 2023 From Mind Medicine (MindMed) Inc. Via Business Wire So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index August 13, 2023 The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. Via Talk Markets MindMed's Q2 2023: One Of Biggest Players In The Space Sustains Faith In LSD's Multiple Path Ahead August 07, 2023 Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this: Via Benzinga MindMed Reports Second Quarter 2023 Financial Results and Business Highlights August 03, 2023 From MindMed Via Business Wire Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More August 03, 2023 A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... Via Benzinga MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120 August 03, 2023 From Mind Medicine (MindMed) Inc Via Business Wire MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update July 31, 2023 From Mind Medicine (MindMed) Inc. Via Business Wire July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average July 30, 2023 All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: Via Talk Markets Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial July 28, 2023 UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: Via Benzinga Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 July 26, 2023 EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END Via FinancialNewsMedia Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD July 23, 2023 The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... Via Talk Markets < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.